Click on the download button below to download The Novozymes Report 2014 in PDF format.

Mark or unmark sections to create your own personal edition of The Novozymes Report 2014. The section "Supplementary" is not included in the official report, but can be added to your personal edition of the report (My extract).

  •  The big picture
  •  Performance
  •  Business & strategy
  •  Governance
  •  Accounts & data
  •  Supplementary

The year in brief

48%

MARKET LEADER IN INDUSTRIAL ENZYMES

With an estimated 48% of the global enzyme market in 2014, Novozymes has strengthened its position as the world’s leading producer of industrial enzymes.

ORGANIC SALES GROWTH

7%

EBIT MARGIN

27.2%

ROIC

23.1%

CO2 emission reduction

In 2014, customers reduced their CO2 emissions by an estimated 60 million tons through the application of Novozymes’ products, equivalent to taking 25 million cars off the road.

Industry & Sales growth in 2014

FREQUENCY OF ACCIDENTS at an all-time low

In 2014, we reached an all-time low frequency of occupational accidents with leave of 1.7 per million working hours.

New long-term targets

Impact targets

REACH

6 billion people with our biological solutions

by 2020

Educate

1 million people about the potential of biology

from 2015 to 2020

Catalyze

5 global partnerships for change

from 2015 to 2020

Deliver

10 transformative innovations

from 2015 to 2020

Save

100 million tons of CO2

by 2020

Enable

Novozymes’ employees to develop

by 2020

Financial targets

8-10%

organic sales growth on average

≥ 26%

EBIT margin

≥ 25%

ROIC incl. goodwill

Novozymes world-wide

R&D

Production

Sales & Marketing

Other services

View

  • World 
  • Region  
    • North America
    • Latin America
    • Europe, middle East & Africa
    • Asia Pacific
  • Location  
    • Blair
    • Cambridge
    • Davis
    • Franklinton
    • Houston
    • Milwaukee
    • New York
    • Ottawa
    • Salem
    • Saskatoon
    • Washington
    • Araucária
    • Mexico
    • Pilar
    • Quatro Barras
    • Bagsværd
    • Fuglebakken
    • Kalundborg
    • Brussels
    • France
    • Nottingham
    • Russia
    • South Africa
    • Switzerland
    • Turkey
    • Australia
    • Beijing
    • BHA TEDA
    • Guangzhou
    • Hongda
    • Hosur
    • Japan
    • Korea
    • Malaysia
    • Pakistan
    • Shandong
    • Tianjin
Join us - North America
The BioAg Alliance
Medley®
Bioenergy: Discover more - Deliver more
Join us - Latin America
Handwash made easier
Medley®
Join us
Enzymes' impact on professional businesses
Medley®
Join us
Handwash made easier
Medley®
Enzymes' impact on professional businesses

Five-year summary

The year in brief

DKK million   2014 2013 2012 2011 2010
             
Income statement            
Revenue   12,459  11,746  11,234  10,510  9,724 
Gross profit   7,149  6,716  6,423  5,908  5,412 
EBITDA   4,400  3,639  3,448  3,126  2,796 
Operating profit / EBIT   3,384  2,901  2,745  2,340  2,117 
Financial items, net   (105) (142) (161) 75 
Net profit   2,525  2,201  2,016  1,828  1,614 
             
Balance sheet            
Total assets   18,426  16,506  15,113  13,842  12,593 
Shareholders' equity   11,280  11,066  9,568  8,824  7,836 
Invested capital   10,535  11,871  10,998  9,843  8,182 
Net interest-bearing debt   (716) 805  1,430  1,019  346 
             
Investments and cash flows            
Cash flow from operating activities   4,525  2,599  2,758  2,709  2,324 
Purchases of property, plant and equipment   703  762  1,128  1,290  1,326 
Net investments excluding acquisitions and The BioAg Alliance impact   715  783  1,177  1,316  1,326 
Free cash flow before net acquisitions and securities   4,229  1,816  1,581  1,393  998 
Business acquisitions and purchase of financial assets   14  640  732  1,530  23 
Free cash flow   4,215  1,176  849  (33) 975 

The year in brief

    2014 2013 2012 2011 2010
             
Key ratios            
Revenue growth, DKK % 15 
Revenue growth, LCY % 10  10 
Revenue growth, organic % 11 
R&D costs (% of revenue) %  14.8  13.0  13.6  13.9  14.0
Gross margin %  57.4  57.2  57.2  56.2  55.7
EBITDA margin %  35.3  31.0  30.7  29.7  28.8
EBIT margin %  27.2  24.7  24.4  22.3  21.8
Effective tax rate %  23.0  20.2  22.0  24.3  24.0
Equity ratio %  61.2  67.0  63.3  63.7  62.2
NIBD/EBITDA   (0.2) 0.2  0.4  0.3  0.1 
Return on equity %  22.6  21.3  21.9  21.9  23.6
ROIC including goodwill %  23.1  20.0  19.9  21.3  22.2
WACC after tax %  3.7  4.7  4.7  4.5  5.6
Earnings per share (EPS), diluted DKK  8.02  6.93  6.33  5.71  5.05
Dividend per share (2014 proposed) DKK  3.00  2.50  2.20  1.90  1.60
Key ratios have been prepared in accordance with the Danish Society of Financial Analysts' "Recommendations & Financial Ratios 2010"
             
Environmental and social data            
Total number of employees No. 6,454  6,236  6,041  5,824  5,432 
Rate of employee turnover % 8.1  7.5  8.1  8.3  7.5 
Frequency of accidents with absence per million working hours   1,7 2.4  3.0  4.3  4.1 
Employee satisfaction Score 77  77  78  77  76 
Development opportunities Score 75  74  75  74  73 
New leaders appointed who are women % 34  26  37  n.a. n.a.
Estimated CO2 reductions from customers' application of Novozymes' products Million tons 60  52  48  45  40